Media stories about ABIOMED (NASDAQ:ABMD) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ABIOMED earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 46.8562623444202 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of ABIOMED (NASDAQ ABMD) traded up $0.12 during trading on Wednesday, hitting $193.06. The company had a trading volume of 177,320 shares, compared to its average volume of 337,985. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20. ABIOMED has a 1 year low of $103.53 and a 1 year high of $200.28. The firm has a market cap of $8,552.73, a P/E ratio of 123.99, a P/E/G ratio of 2.58 and a beta of 0.15.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.16. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The firm had revenue of $132.80 million during the quarter, compared to the consensus estimate of $131.18 million. During the same period in the previous year, the firm posted $0.20 EPS. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. equities research analysts expect that ABIOMED will post 2.38 earnings per share for the current fiscal year.

Several research analysts recently issued reports on ABMD shares. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective for the company in a research report on Tuesday, November 7th. SunTrust Banks restated a “buy” rating and set a $195.00 price objective on shares of ABIOMED in a research report on Wednesday, November 1st. Jefferies Group lifted their price objective on ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a research report on Friday, September 29th. Piper Jaffray Companies restated a “buy” rating and set a $160.00 price objective on shares of ABIOMED in a research report on Tuesday, August 29th. Finally, BidaskClub downgraded ABIOMED from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. ABIOMED presently has a consensus rating of “Buy” and an average target price of $190.43.

In other ABIOMED news, Director Dorothy E. Puhy sold 6,364 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $179.08, for a total value of $1,139,665.12. Following the completion of the transaction, the director now directly owns 39,532 shares in the company, valued at approximately $7,079,390.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Andrew J. Greenfield sold 11,282 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $169.32, for a total value of $1,910,268.24. The disclosure for this sale can be found here. Insiders sold a total of 27,646 shares of company stock valued at $4,836,333 over the last quarter. 7.00% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “ABIOMED (ABMD) Given Daily Media Impact Score of 0.17” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/abiomed-abmd-given-daily-media-impact-score-of-0-17/1762244.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Insider Buying and Selling by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.